Infliximab biosimilar CT-P13 therapy in patients with Takayasu arteritis with low dose of glucocorticoids: a prospective single-arm study View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2018-09-18

AUTHORS

Eun Hye Park, Eun Young Lee, Yun Jong Lee, You Jung Ha, Wan-Hee Yoo, Byoong Yong Choi, Jin Chul Paeng, Hoon Young Suh, Yeong Wook Song

ABSTRACT

To evaluate the efficacy and safety of infliximab biosimilar CT-P13 in patients with active Takayasu arteritis (TAK). In this single-center open-label trial, patients with active TAK received CT-P13 at a starting dose of 5 mg/kg at weeks 0, 2, 6, and then every 8 weeks up to week 46. They were followed up until week 54. From week 14 to week 46, patients with inadequate response received increased dose of CT-P13 by 1.5 mg/kg. Concomitant prednisolone was allowed ≤ 10 mg/day. The primary efficacy end point was the achievement of partial or complete remission at week 30. All patients underwent positron emission tomography–computed tomography (PET–CT) at baseline and week 30. Twelve patients with TAK received CT-P13; one patient with protocol violation was excluded from analysis. Nine (81.8%) patients had taken concomitant prednisolone with median dose of 5.0 mg/day. At week 30, three (27.3%) patients achieved complete remission and six (54.5%) patients achieved partial remission. Statistically significant improvements in modified Indian Takayasu Clinical Activity Score (ITAS2010), ITAS-A, and serum levels of erythrocyte sedimentation rate and C-reactive protein were seen at week 30 from baseline. PET parameters were significantly reduced from baseline to week 30, including maximum standardized uptake value, target-to-vein ratio, target-to-liver ratio, and PET Vascular Activity Score. There were no serious adverse events. Treatment with CT-P13 may lead to improvement in clinical, radiographic, and serological activities with lower glucocorticoid requirement in TAK.Trial registration number NCT02457585. More... »

PAGES

2233-2242

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00296-018-4159-1

DOI

http://dx.doi.org/10.1007/s00296-018-4159-1

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1107089445

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30229280


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Anti-Inflammatory Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Monoclonal", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Biomarkers", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Biosimilar Pharmaceuticals", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Blood Sedimentation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "C-Reactive Protein", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Therapy, Combination", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Glucocorticoids", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Inflammation Mediators", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Positron Emission Tomography Computed Tomography", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prednisolone", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Remission Induction", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Takayasu Arteritis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Time Factors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, 101, Daehak-ro, Jongno-gu, Seoul, South Korea", 
          "id": "http://www.grid.ac/institutes/grid.412484.f", 
          "name": [
            "Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, 101, Daehak-ro, Jongno-gu, Seoul, South Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Park", 
        "givenName": "Eun Hye", 
        "id": "sg:person.0730324761.38", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0730324761.38"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, 101, Daehak-ro, Jongno-gu, Seoul, South Korea", 
          "id": "http://www.grid.ac/institutes/grid.412484.f", 
          "name": [
            "Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, 101, Daehak-ro, Jongno-gu, Seoul, South Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lee", 
        "givenName": "Eun Young", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea", 
          "id": "http://www.grid.ac/institutes/grid.412480.b", 
          "name": [
            "Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lee", 
        "givenName": "Yun Jong", 
        "id": "sg:person.01050556173.39", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01050556173.39"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea", 
          "id": "http://www.grid.ac/institutes/grid.412480.b", 
          "name": [
            "Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ha", 
        "givenName": "You Jung", 
        "id": "sg:person.0772213645.45", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0772213645.45"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Rheumatology, Department of Internal Medicine, Chonbuk National University, Jeonju, South Korea", 
          "id": "http://www.grid.ac/institutes/grid.411545.0", 
          "name": [
            "Division of Rheumatology, Department of Internal Medicine, Chonbuk National University, Jeonju, South Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yoo", 
        "givenName": "Wan-Hee", 
        "id": "sg:person.01255505235.37", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01255505235.37"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Internal Medicine, Seoul Medical Center, Seoul, South Korea", 
          "id": "http://www.grid.ac/institutes/grid.415520.7", 
          "name": [
            "Department of Internal Medicine, Seoul Medical Center, Seoul, South Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Choi", 
        "givenName": "Byoong Yong", 
        "id": "sg:person.01242364624.47", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01242364624.47"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Nuclear Medicine, Seoul National University Hospital, Seoul, South Korea", 
          "id": "http://www.grid.ac/institutes/grid.412484.f", 
          "name": [
            "Department of Nuclear Medicine, Seoul National University Hospital, Seoul, South Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Paeng", 
        "givenName": "Jin Chul", 
        "id": "sg:person.01343511335.32", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01343511335.32"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Nuclear Medicine, Seoul National University Hospital, Seoul, South Korea", 
          "id": "http://www.grid.ac/institutes/grid.412484.f", 
          "name": [
            "Department of Nuclear Medicine, Seoul National University Hospital, Seoul, South Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Suh", 
        "givenName": "Hoon Young", 
        "id": "sg:person.07644213235.35", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07644213235.35"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology and College of Medicine, Medical Research Center, Seoul National University, Seoul, South Korea", 
          "id": "http://www.grid.ac/institutes/grid.31501.36", 
          "name": [
            "Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, 101, Daehak-ro, Jongno-gu, Seoul, South Korea", 
            "Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology and College of Medicine, Medical Research Center, Seoul National University, Seoul, South Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Song", 
        "givenName": "Yeong Wook", 
        "id": "sg:person.016420253074.70", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016420253074.70"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s10067-013-2380-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025925805", 
          "https://doi.org/10.1007/s10067-013-2380-6"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10067-006-0227-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053211451", 
          "https://doi.org/10.1007/s10067-006-0227-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10067-010-1658-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001531894", 
          "https://doi.org/10.1007/s10067-010-1658-1"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2018-09-18", 
    "datePublishedReg": "2018-09-18", 
    "description": "To evaluate the efficacy and safety of infliximab biosimilar CT-P13 in patients with active Takayasu arteritis (TAK). In this single-center open-label trial, patients with active TAK received CT-P13 at a starting dose of 5\u00a0mg/kg at weeks 0, 2, 6, and then every 8 weeks up to week 46. They were followed up until week 54. From week 14 to week 46, patients with inadequate response received increased dose of CT-P13 by 1.5\u00a0mg/kg. Concomitant prednisolone was allowed\u2009\u2264\u200910\u00a0mg/day. The primary efficacy end point was the achievement of partial or complete remission at week 30. All patients underwent positron emission tomography\u2013computed tomography (PET\u2013CT) at baseline and week 30. Twelve patients with TAK received CT-P13; one patient with protocol violation was excluded from analysis. Nine (81.8%) patients had taken concomitant prednisolone with median dose of 5.0\u00a0mg/day. At week 30, three (27.3%) patients achieved complete remission and six (54.5%) patients achieved partial remission. Statistically significant improvements in modified Indian Takayasu Clinical Activity Score (ITAS2010), ITAS-A, and serum levels of erythrocyte sedimentation rate and C-reactive protein were seen at week 30 from baseline. PET parameters were significantly reduced from baseline to week 30, including maximum standardized uptake value, target-to-vein ratio, target-to-liver ratio, and PET Vascular Activity Score. There were no serious adverse events. Treatment with CT-P13 may lead to improvement in clinical, radiographic, and serological activities with lower glucocorticoid requirement in TAK.Trial registration number NCT02457585.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00296-018-4159-1", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1093123", 
        "issn": [
          "0172-8172", 
          "1437-160X"
        ], 
        "name": "Rheumatology International", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "12", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "38"
      }
    ], 
    "keywords": [
      "active Takayasu arteritis", 
      "Takayasu arteritis", 
      "CT-P13", 
      "week 30", 
      "concomitant prednisolone", 
      "complete remission", 
      "activity score", 
      "week 46", 
      "single-center open-label trial", 
      "Indian Takayasu Clinical Activity Score", 
      "infliximab biosimilar CT-P13", 
      "primary efficacy end point", 
      "PET vascular activity score", 
      "prospective single-arm study", 
      "positron emission tomography-computed tomography", 
      "emission tomography-computed tomography", 
      "maximum standardized uptake value", 
      "biosimilar CT-P13", 
      "efficacy end point", 
      "CT-P13 therapy", 
      "open-label trial", 
      "clinical activity score", 
      "serious adverse events", 
      "single-arm study", 
      "erythrocyte sedimentation rate", 
      "C-reactive protein", 
      "tomography-computed tomography", 
      "standardized uptake value", 
      "glucocorticoid requirement", 
      "starting dose", 
      "partial remission", 
      "week 54", 
      "median dose", 
      "serum levels", 
      "adverse events", 
      "weeks 0", 
      "increased dose", 
      "protocol violations", 
      "inadequate response", 
      "vein ratio", 
      "week 14", 
      "PET parameters", 
      "liver ratio", 
      "low dose", 
      "patients", 
      "uptake value", 
      "remission", 
      "end point", 
      "dose", 
      "serological activity", 
      "baseline", 
      "arteritis", 
      "prednisolone", 
      "sedimentation rate", 
      "significant improvement", 
      "scores", 
      "days", 
      "glucocorticoids", 
      "therapy", 
      "trials", 
      "weeks", 
      "efficacy", 
      "tomography", 
      "target", 
      "treatment", 
      "ITAS", 
      "safety", 
      "improvement", 
      "response", 
      "levels", 
      "protein", 
      "activity", 
      "study", 
      "ratio", 
      "rate", 
      "events", 
      "analysis", 
      "values", 
      "point", 
      "parameters", 
      "achievement", 
      "requirements", 
      "violation"
    ], 
    "name": "Infliximab biosimilar CT-P13 therapy in patients with Takayasu arteritis with low dose of glucocorticoids: a prospective single-arm study", 
    "pagination": "2233-2242", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1107089445"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00296-018-4159-1"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30229280"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00296-018-4159-1", 
      "https://app.dimensions.ai/details/publication/pub.1107089445"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-10-01T06:44", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221001/entities/gbq_results/article/article_779.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00296-018-4159-1"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00296-018-4159-1'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00296-018-4159-1'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00296-018-4159-1'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00296-018-4159-1'


 

This table displays all metadata directly associated to this object as RDF triples.

310 TRIPLES      21 PREDICATES      132 URIs      121 LITERALS      28 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00296-018-4159-1 schema:about N0205a13bb2b741199dbba072f0a37b17
2 N0b140183fbfe4d078a403c3e8227af0d
3 N2a8c278a6e75424b9361737a52d68f57
4 N35f9f227c9ec43faa4e7a886115da60c
5 N365cb28969ae4c0e89a15a270ea88e5f
6 N382de3483b7b48ca9f4eda58b449ae3d
7 N387aca464a464b8c97153b1d8b462738
8 N41111f9dd70940a49f700287bfaae178
9 N4c97cc5ec9e742079a4e29e1661afe3f
10 N54eb2f49ee3f43079613ad3af18fbe1a
11 N812a88a7b2da4ee2ab08a3092730161e
12 N814018c107074dc281b63ac14bb40b79
13 N85bbda36406345059d741d19027eb277
14 N8da867145c8f4ab79e4a06925068fc81
15 N8e9dcc783d0446d2859c3583771b4f72
16 N8f6d611425b7456c917d9400edd382c6
17 Nb8697b920f004869a5bcb49af467c04a
18 Nc48d3f0c09f541febcfcdd78a3be7a44
19 Nd5a0e76a1edb42739255627849656ca1
20 Ndc5104e156e1434db45978eb6151c69c
21 Neea1cdb60e1f4270b4d28e80f90d927f
22 anzsrc-for:11
23 anzsrc-for:1103
24 schema:author Nf692f02452c449aeb1dececc06cd4af2
25 schema:citation sg:pub.10.1007/s10067-006-0227-0
26 sg:pub.10.1007/s10067-010-1658-1
27 sg:pub.10.1007/s10067-013-2380-6
28 schema:datePublished 2018-09-18
29 schema:datePublishedReg 2018-09-18
30 schema:description To evaluate the efficacy and safety of infliximab biosimilar CT-P13 in patients with active Takayasu arteritis (TAK). In this single-center open-label trial, patients with active TAK received CT-P13 at a starting dose of 5 mg/kg at weeks 0, 2, 6, and then every 8 weeks up to week 46. They were followed up until week 54. From week 14 to week 46, patients with inadequate response received increased dose of CT-P13 by 1.5 mg/kg. Concomitant prednisolone was allowed ≤ 10 mg/day. The primary efficacy end point was the achievement of partial or complete remission at week 30. All patients underwent positron emission tomography–computed tomography (PET–CT) at baseline and week 30. Twelve patients with TAK received CT-P13; one patient with protocol violation was excluded from analysis. Nine (81.8%) patients had taken concomitant prednisolone with median dose of 5.0 mg/day. At week 30, three (27.3%) patients achieved complete remission and six (54.5%) patients achieved partial remission. Statistically significant improvements in modified Indian Takayasu Clinical Activity Score (ITAS2010), ITAS-A, and serum levels of erythrocyte sedimentation rate and C-reactive protein were seen at week 30 from baseline. PET parameters were significantly reduced from baseline to week 30, including maximum standardized uptake value, target-to-vein ratio, target-to-liver ratio, and PET Vascular Activity Score. There were no serious adverse events. Treatment with CT-P13 may lead to improvement in clinical, radiographic, and serological activities with lower glucocorticoid requirement in TAK.Trial registration number NCT02457585.
31 schema:genre article
32 schema:isAccessibleForFree true
33 schema:isPartOf N2114fece736e4402bb59e7ecc54c5e57
34 Nbdf228fbb84844599a7c77d3b54269da
35 sg:journal.1093123
36 schema:keywords C-reactive protein
37 CT-P13
38 CT-P13 therapy
39 ITAS
40 Indian Takayasu Clinical Activity Score
41 PET parameters
42 PET vascular activity score
43 Takayasu arteritis
44 achievement
45 active Takayasu arteritis
46 activity
47 activity score
48 adverse events
49 analysis
50 arteritis
51 baseline
52 biosimilar CT-P13
53 clinical activity score
54 complete remission
55 concomitant prednisolone
56 days
57 dose
58 efficacy
59 efficacy end point
60 emission tomography-computed tomography
61 end point
62 erythrocyte sedimentation rate
63 events
64 glucocorticoid requirement
65 glucocorticoids
66 improvement
67 inadequate response
68 increased dose
69 infliximab biosimilar CT-P13
70 levels
71 liver ratio
72 low dose
73 maximum standardized uptake value
74 median dose
75 open-label trial
76 parameters
77 partial remission
78 patients
79 point
80 positron emission tomography-computed tomography
81 prednisolone
82 primary efficacy end point
83 prospective single-arm study
84 protein
85 protocol violations
86 rate
87 ratio
88 remission
89 requirements
90 response
91 safety
92 scores
93 sedimentation rate
94 serious adverse events
95 serological activity
96 serum levels
97 significant improvement
98 single-arm study
99 single-center open-label trial
100 standardized uptake value
101 starting dose
102 study
103 target
104 therapy
105 tomography
106 tomography-computed tomography
107 treatment
108 trials
109 uptake value
110 values
111 vein ratio
112 violation
113 week 14
114 week 30
115 week 46
116 week 54
117 weeks
118 weeks 0
119 schema:name Infliximab biosimilar CT-P13 therapy in patients with Takayasu arteritis with low dose of glucocorticoids: a prospective single-arm study
120 schema:pagination 2233-2242
121 schema:productId N1adcb9a5201447af807a8abbde54da3a
122 N6f3ee4463b0742f788998aef458ce236
123 Ne2ba759b006d44bca10d71e3a09a39ef
124 schema:sameAs https://app.dimensions.ai/details/publication/pub.1107089445
125 https://doi.org/10.1007/s00296-018-4159-1
126 schema:sdDatePublished 2022-10-01T06:44
127 schema:sdLicense https://scigraph.springernature.com/explorer/license/
128 schema:sdPublisher Nb89471b0458f4527a0cc27930d0c0b1e
129 schema:url https://doi.org/10.1007/s00296-018-4159-1
130 sgo:license sg:explorer/license/
131 sgo:sdDataset articles
132 rdf:type schema:ScholarlyArticle
133 N0205a13bb2b741199dbba072f0a37b17 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
134 schema:name Female
135 rdf:type schema:DefinedTerm
136 N0b140183fbfe4d078a403c3e8227af0d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Anti-Inflammatory Agents
138 rdf:type schema:DefinedTerm
139 N1adcb9a5201447af807a8abbde54da3a schema:name doi
140 schema:value 10.1007/s00296-018-4159-1
141 rdf:type schema:PropertyValue
142 N2114fece736e4402bb59e7ecc54c5e57 schema:volumeNumber 38
143 rdf:type schema:PublicationVolume
144 N240fef6259dc471a82a339d872f1a021 rdf:first sg:person.01343511335.32
145 rdf:rest N7fc8275ab612443ebb5df6d30b86a4c1
146 N2a8c278a6e75424b9361737a52d68f57 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Biosimilar Pharmaceuticals
148 rdf:type schema:DefinedTerm
149 N35f9f227c9ec43faa4e7a886115da60c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
150 schema:name Prednisolone
151 rdf:type schema:DefinedTerm
152 N365cb28969ae4c0e89a15a270ea88e5f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
153 schema:name Blood Sedimentation
154 rdf:type schema:DefinedTerm
155 N382de3483b7b48ca9f4eda58b449ae3d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
156 schema:name Male
157 rdf:type schema:DefinedTerm
158 N387aca464a464b8c97153b1d8b462738 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
159 schema:name Takayasu Arteritis
160 rdf:type schema:DefinedTerm
161 N41111f9dd70940a49f700287bfaae178 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
162 schema:name Remission Induction
163 rdf:type schema:DefinedTerm
164 N4c97cc5ec9e742079a4e29e1661afe3f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
165 schema:name Time Factors
166 rdf:type schema:DefinedTerm
167 N54eb2f49ee3f43079613ad3af18fbe1a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
168 schema:name Treatment Outcome
169 rdf:type schema:DefinedTerm
170 N6f3ee4463b0742f788998aef458ce236 schema:name dimensions_id
171 schema:value pub.1107089445
172 rdf:type schema:PropertyValue
173 N7fc8275ab612443ebb5df6d30b86a4c1 rdf:first sg:person.07644213235.35
174 rdf:rest Nff69c19190f64e67a1af434dff5005bb
175 N812a88a7b2da4ee2ab08a3092730161e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
176 schema:name Humans
177 rdf:type schema:DefinedTerm
178 N814018c107074dc281b63ac14bb40b79 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
179 schema:name Glucocorticoids
180 rdf:type schema:DefinedTerm
181 N85bbda36406345059d741d19027eb277 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
182 schema:name Middle Aged
183 rdf:type schema:DefinedTerm
184 N8da867145c8f4ab79e4a06925068fc81 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
185 schema:name Adult
186 rdf:type schema:DefinedTerm
187 N8e9dcc783d0446d2859c3583771b4f72 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
188 schema:name Inflammation Mediators
189 rdf:type schema:DefinedTerm
190 N8f6d611425b7456c917d9400edd382c6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
191 schema:name Drug Therapy, Combination
192 rdf:type schema:DefinedTerm
193 N94e2b4522bb9425e9cc930d7bdc6e0e7 rdf:first Nac7599c78e5149aabc2d5aff23302086
194 rdf:rest Ncdf28cd384ad46d392ca21550ed7743a
195 Nac7599c78e5149aabc2d5aff23302086 schema:affiliation grid-institutes:grid.412484.f
196 schema:familyName Lee
197 schema:givenName Eun Young
198 rdf:type schema:Person
199 Nb8697b920f004869a5bcb49af467c04a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
200 schema:name Biomarkers
201 rdf:type schema:DefinedTerm
202 Nb89471b0458f4527a0cc27930d0c0b1e schema:name Springer Nature - SN SciGraph project
203 rdf:type schema:Organization
204 Nbdf228fbb84844599a7c77d3b54269da schema:issueNumber 12
205 rdf:type schema:PublicationIssue
206 Nc48d3f0c09f541febcfcdd78a3be7a44 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
207 schema:name C-Reactive Protein
208 rdf:type schema:DefinedTerm
209 Ncdf28cd384ad46d392ca21550ed7743a rdf:first sg:person.01050556173.39
210 rdf:rest Nf525bbe6d9e0496abbfb192031db51e1
211 Nd5a0e76a1edb42739255627849656ca1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
212 schema:name Prospective Studies
213 rdf:type schema:DefinedTerm
214 Ndc5104e156e1434db45978eb6151c69c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
215 schema:name Antibodies, Monoclonal
216 rdf:type schema:DefinedTerm
217 Ne2ba759b006d44bca10d71e3a09a39ef schema:name pubmed_id
218 schema:value 30229280
219 rdf:type schema:PropertyValue
220 Neea1cdb60e1f4270b4d28e80f90d927f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
221 schema:name Positron Emission Tomography Computed Tomography
222 rdf:type schema:DefinedTerm
223 Nf525bbe6d9e0496abbfb192031db51e1 rdf:first sg:person.0772213645.45
224 rdf:rest Nf5421835a5114d368357ee79aaeaa8da
225 Nf5421835a5114d368357ee79aaeaa8da rdf:first sg:person.01255505235.37
226 rdf:rest Nfcf92da97a4247178534c789d2cd7bcf
227 Nf692f02452c449aeb1dececc06cd4af2 rdf:first sg:person.0730324761.38
228 rdf:rest N94e2b4522bb9425e9cc930d7bdc6e0e7
229 Nfcf92da97a4247178534c789d2cd7bcf rdf:first sg:person.01242364624.47
230 rdf:rest N240fef6259dc471a82a339d872f1a021
231 Nff69c19190f64e67a1af434dff5005bb rdf:first sg:person.016420253074.70
232 rdf:rest rdf:nil
233 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
234 schema:name Medical and Health Sciences
235 rdf:type schema:DefinedTerm
236 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
237 schema:name Clinical Sciences
238 rdf:type schema:DefinedTerm
239 sg:journal.1093123 schema:issn 0172-8172
240 1437-160X
241 schema:name Rheumatology International
242 schema:publisher Springer Nature
243 rdf:type schema:Periodical
244 sg:person.01050556173.39 schema:affiliation grid-institutes:grid.412480.b
245 schema:familyName Lee
246 schema:givenName Yun Jong
247 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01050556173.39
248 rdf:type schema:Person
249 sg:person.01242364624.47 schema:affiliation grid-institutes:grid.415520.7
250 schema:familyName Choi
251 schema:givenName Byoong Yong
252 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01242364624.47
253 rdf:type schema:Person
254 sg:person.01255505235.37 schema:affiliation grid-institutes:grid.411545.0
255 schema:familyName Yoo
256 schema:givenName Wan-Hee
257 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01255505235.37
258 rdf:type schema:Person
259 sg:person.01343511335.32 schema:affiliation grid-institutes:grid.412484.f
260 schema:familyName Paeng
261 schema:givenName Jin Chul
262 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01343511335.32
263 rdf:type schema:Person
264 sg:person.016420253074.70 schema:affiliation grid-institutes:grid.31501.36
265 schema:familyName Song
266 schema:givenName Yeong Wook
267 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016420253074.70
268 rdf:type schema:Person
269 sg:person.0730324761.38 schema:affiliation grid-institutes:grid.412484.f
270 schema:familyName Park
271 schema:givenName Eun Hye
272 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0730324761.38
273 rdf:type schema:Person
274 sg:person.07644213235.35 schema:affiliation grid-institutes:grid.412484.f
275 schema:familyName Suh
276 schema:givenName Hoon Young
277 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07644213235.35
278 rdf:type schema:Person
279 sg:person.0772213645.45 schema:affiliation grid-institutes:grid.412480.b
280 schema:familyName Ha
281 schema:givenName You Jung
282 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0772213645.45
283 rdf:type schema:Person
284 sg:pub.10.1007/s10067-006-0227-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053211451
285 https://doi.org/10.1007/s10067-006-0227-0
286 rdf:type schema:CreativeWork
287 sg:pub.10.1007/s10067-010-1658-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001531894
288 https://doi.org/10.1007/s10067-010-1658-1
289 rdf:type schema:CreativeWork
290 sg:pub.10.1007/s10067-013-2380-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025925805
291 https://doi.org/10.1007/s10067-013-2380-6
292 rdf:type schema:CreativeWork
293 grid-institutes:grid.31501.36 schema:alternateName Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology and College of Medicine, Medical Research Center, Seoul National University, Seoul, South Korea
294 schema:name Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology and College of Medicine, Medical Research Center, Seoul National University, Seoul, South Korea
295 Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, 101, Daehak-ro, Jongno-gu, Seoul, South Korea
296 rdf:type schema:Organization
297 grid-institutes:grid.411545.0 schema:alternateName Division of Rheumatology, Department of Internal Medicine, Chonbuk National University, Jeonju, South Korea
298 schema:name Division of Rheumatology, Department of Internal Medicine, Chonbuk National University, Jeonju, South Korea
299 rdf:type schema:Organization
300 grid-institutes:grid.412480.b schema:alternateName Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea
301 schema:name Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea
302 rdf:type schema:Organization
303 grid-institutes:grid.412484.f schema:alternateName Department of Nuclear Medicine, Seoul National University Hospital, Seoul, South Korea
304 Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, 101, Daehak-ro, Jongno-gu, Seoul, South Korea
305 schema:name Department of Nuclear Medicine, Seoul National University Hospital, Seoul, South Korea
306 Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, 101, Daehak-ro, Jongno-gu, Seoul, South Korea
307 rdf:type schema:Organization
308 grid-institutes:grid.415520.7 schema:alternateName Department of Internal Medicine, Seoul Medical Center, Seoul, South Korea
309 schema:name Department of Internal Medicine, Seoul Medical Center, Seoul, South Korea
310 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...